Últimas noticias sobre Hancock Whitney (NASDAQ:HWC) Bolsa

HANCOCK WHITNEY CORP

Hancock Whitney

Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business, and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit, and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations, and individuals and provides its customers access to investment advisory and brokerage products.

Hancock Whitney Corporation - Common Stock

Hancock Whitney Corp

Hancock Whitney Corporation - 6.25% Subordinated Notes due 2060

<a href="https://www.bloomberg.com/news/articles/2025-07-08/eu-trade-deal-with-us-may-spare-airbus-from-worst-tariffs-impact" title="https://www.bloomberg.com/news/articles/2025-07-08/eu-trade-deal-with-us-may-spare-airbus-from-worst-tariffs-impact">https://www.bloomberg.com/news/articles/2025-07-08/eu-trade-deal-with-us-may-spare-airbus-from-worst-tariffs-impact</a>

Macro Economic Events

News

Global

Economics

European Aeronautic Defence And Space Unsponsored

EADSY

RACE

'EU to Protect Airbus in US Trade Deal as Ferrari Set to Lose Out' - Bloomberg News

WIIM

MMSI

Merit Medical Systems shares are trading higher after the company announced it appointed a new CEO. Additionally, Needham and Piper Sandler maintained Buy ratings on the stock.

TD Cowen analyst Jeffrey Osborne downgrades TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) from Buy to Hold and lowers the price target from $2 to $1.

Downgrades

Price Target

Analyst Ratings

TPIC

TD Cowen Downgrades TPI Composites to Hold, Lowers Price Target to $1

Raymond James analyst C. Gregory Peters reiterates HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Strong Buy and raises the price target from $115 to $120.

Reiteration

Raymond James Reiterates Strong Buy on HealthEquity, Raises Price Target to $120

TD Cowen analyst Moshe Orenbuch upgrades Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) from Hold to Buy and raises the price target from $184 to $258.

Upgrades

TD Cowen Upgrades Capital One Finl to Buy, Raises Price Target to $258

AMAT

Applied Materials shares are trading higher after Wells Fargo maintained an Overweight rating and raised the price target from $200 to $215.

Raymond James analyst Brian Gesuale upgrades Parsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) from Market Perform to Strong Buy and announces $90 price target.

Raymond James Upgrades Parsons to Strong Buy, Announces $90 Price Target

Raymond James analyst Brian Gesuale downgrades CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) from Outperform to Market Perform.

CACI

Raymond James Downgrades CACI International to Market Perform

LCID

Lucid Group shares are trading higher after the company set a 749-mile new Guinness World Record for the longest journey by an electric car on a single charge.

Raymond James analyst Daniel Tamayo reiterates Wintrust Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) with a Strong Buy and raises the price target from $143 to $155.

WTFC

Raymond James Reiterates Strong Buy on Wintrust Financial, Raises Price Target to $155

Politics

General

INDA

President Trump Says BRICS Is Getting 10% Charge Pretty Soon; Not Going To Lose The Standard Anytime; EU Has Been Speaking To Us; EU Treating Us Very Nicely; Probably Two Days Off From Sending EU Letter

Raymond James analyst Daniel Tamayo reiterates Webster Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) with a Outperform and raises the price target from $58 to $65.

Raymond James Reiterates Outperform on Webster Financial, Raises Price Target to $65

ALTG

Alta Equipment Group shares are trading higher after Northland Capital Markets upgraded the stock from Market Perform to Outperform and announced a $20 price target.

Raymond James analyst Daniel Tamayo downgrades United Community Banks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UCB#NYSE">UCB</a>) from Outperform to Market Perform.

Raymond James Downgrades United Community Banks to Market Perform

Bank of America shares are trading lower after HSBC downgraded the stock from Buy to Hold, despite raising the price target from $47 to $51.

The U.S. defense budget just got a historic boost and Goldman Sachs believes a group of arms contractors could be primed for a surge in revenue, growth and market interest as the Pentagon begins deploying its <a href="https://www.benzinga.com/money/best-aerospace-defense-stocks">$156.2 billion in fresh funding.</a>
Following President Donald Trump's <a href="https://www.benzinga.com/news/politics/25/07/46263434/trump-signs-sweeping-tax-and-spending-bill-that-cbo-says-will-add-3-3-trillion-to-us-deficit-cut-health-coverage-for-11-8-million-americans">July 4th signing</a> of the "One Big Beautiful Bill Act," the Department of Defense is set to receive targeted appropriations for core programs such as shipbuilding, missile defense, nuclear systems and low-cost autonomous technologies.
In a note shared on Tuesday, Goldman Sachs analyst Noah Poponak identified four defense stocks that stand out as key beneficiaries of this legislation.
What's In The New Defense Budget?
Title II of the new legislation&#8217;s tax directs $156.2 billion in appropriations across 13 specific defense categories. Highlights include:
<ul class="wp-block-list">
<li>$29.2 billion for shipbuilding</li>
<li>$24.4 billion for integrated air and missile defense (Golden Dome)</li>
<li>$25.4 billion for munitions and supply chain resilience</li>
<li>$16.0 billion for scaling low-cost weapons</li>
<li>$8.6 billion for air superiority initiatives</li>
<li>$10.8 billion for nuclear force modernization</li>
</ul>
<h3 class="wp-block-heading">Goldman Sachs Says These Defense Stocks Could Soar</h3>
Goldman believes the funding will translate into new awards over the next few years, boosting bookings, organic growth, margins and capacity expansion for these key players:
Huntington Ingalls Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>): Poponak said, "There is substantial support for the maritime workforce and supply chain in the Act," pointing to more than $5 billion in funding tied to industrial base and manufacturing process improvements. HII has already received a $1.3 billion workforce investment award this year, and Goldman expects more to follow, which is expected to lift shipbuilding margins in the near to medium term.
L3Harris Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>): The Act allocates $24.4 billion to Golden Dome, and Goldman believes LHX is well positioned to win tech and satellite contracts in that program. "Aerojet Rocketdyne has technological moats around missile propulsion," the note said, adding that these capabilities align with additional munitions and propulsion funding in the bill.
Kratos Defense &amp; Security Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>): KTOS has invested heavily in lower-cost drones, propulsion systems and space equipment, all of which are central to the Pentagon's current procurement shift. "KTOS's emphasis on lower-cost, technically acceptable products that can be built at scale" matches the Department of Defense's push for affordable and mass-producible solutions.
AeroVironment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>): AVAV's tactical drones, including the Switchblade line, could benefit from the $1.4 billion allocated to small unmanned aerial systems (sUAS). The bill provides additional billions to test, develop and procure sUAS and commercial derivative tech, areas where AVAV is considered a front-runner.
Read now: <a href="https://www.benzinga.com/news/25/07/46280221/vice-stocks-beat-esg-trump-2025">Guns, Booze, And Gambling Stocks Are Crushing ESG In Trump&#8217;s America</a>
Photo: Shutterstock<a href="https://www.benzinga.com/news/25/07/46280221/vice-stocks-beat-esg-trump-2025"> </a>

Analyst Color

Equities

Large Cap

AVAV

KTOS

Pentagon's $156-Billion Payday—These Defense Stocks Are Ready For Liftoff

ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the "Series A-2 Warrants") and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the "Series A-3 Warrants," and together with the Series A-2 Warrants, the "Existing Warrants") at a reduced exercise price of $0.67. Gross cash proceeds were approximately $2.0 million before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
In consideration for the immediate exercise in full of the Existing Warrants, the investor will receive new Series A-4 unregistered warrants in a private placement to purchase up to 6,124,930 shares of common stock (the "Series A-4 Warrants" or the "New Warrants"). The New Warrants will have an exercise price of $0.67 and will be initially exercisable on the date that stockholders approve the exercise of the New Warrants. The New Warrants will expire five years from the date of such approval. The closing of the warrant inducement transaction is expected to occur on or about July 9, 2025, subject to satisfaction of customary closing conditions.
A.G.P./Alliance Global Partners acted as the exclusive financial advisor in connection with the transaction.

Offerings

ZVSA

ZyVersa Therapeutics Enters $2M Warrant Inducement Deal; Issues New Series A-4 Warrants for 6.1M Shares At $0.67 Exercise Price

VOYG

Voyager Technologies shares are trading higher after several firms initiated coverage on the stock and issued bullish ratings ranging from Buy, Overweight, and Outperform.

HSBC analyst Saul Martinez downgrades Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) from Buy to Hold and raises the price target from $47 to $51.

HSBC Downgrades Bank of America to Hold, Raises Price Target to $51

Raymond James analyst Daniel Tamayo upgrades Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) from Market Perform to Outperform and announces $50 price target.

Comments

Hancock Whitney

Noticias

Últimas noticias sobre Hancock Whitney (NASDAQ:HWC) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL